ambossIconambossIcon

Postural orthostatic tachycardia syndrome

Last updated: June 17, 2026

Summarytoggle arrow icon

Postural orthostatic tachycardia syndrome (POTS) is an autonomic disorder characterized by a sustained increase in heart rate during standing, without associated orthostatic hypotension. It predominantly affects adolescent girls and young to middle-aged women. Although the pathogenesis of POTS remains unclear, it is often precipitated by viral illness. Clinical features include orthostatic symptoms (e.g., lightheadedness, palpitations, blurred vision) and nonorthostatic symptoms (e.g., fatigue, cognitive impairment). The active stand test is used to confirm the diagnosis; a tilt table test may be obtained if the active stand test is inconclusive or not tolerated by the patient. Additional workup should be performed as needed to rule out differential diagnoses of POTS, including comorbid conditions. Management focuses on reducing symptoms and optimizing quality of life. Self-management strategies involve increased fluid and salt intake, compression garments, and personalized exercise therapy. Pharmacological therapy, which is often required in addition to lifestyle modifications, includes agents that increase venous return (e.g., midodrine, fludrocortisone) and heart rate-lowering drugs (e.g., propranolol).

Icon of a lock

Register or log in , in order to read the full article.

Epidemiologytoggle arrow icon

  • Prevalence
    • Precise nationwide prevalence data are limited.
    • Previous estimates indicate approx. 0.2–1% [1]
    • Likely significantly higher after the COVID-19 pandemic [2]
  • Sex: > (4:1) [1]
  • Age: typically affects individuals 12–50 years of age [1]

POTS predominantly affects adolescent girls and young to middle-aged women. [1]

Epidemiological data refers to the US, unless otherwise specified.

Icon of a lock

Register or log in , in order to read the full article.

Etiologytoggle arrow icon

The underlying pathophysiology of POTS is complex and multifactorial. [2][3]

POTS is a common manifestation of long COVID, affecting approx. 60% of patients. [5][6]

Icon of a lock

Register or log in , in order to read the full article.

Clinical featurestoggle arrow icon

Clinical features of POTS typically fluctuate over time and may have a relapsing and remitting pattern. [2]

Icon of a lock

Register or log in , in order to read the full article.

Diagnosistoggle arrow icon

Approach [2][4]

The diagnosis of POTS is typically delayed by years and initial misdiagnosis is common. [2][3]

Diagnostic criteria for POTS [1][2]

Active stand test [2][4]

  • Timing and preparation
    • Perform in the morning.
    • Prior to test, the patient should:
      • Fast for ≥ 2 hours [2]
      • Rest supine for 5–10 minutes [2]
  • Method
    • Measure baseline blood pressure and HR in supine position.
    • Repeat BP and HR at regular intervals for up to 10 minutes after standing (e.g., at 1, 3, 5, and 10 minutes). [4]
    • Document any symptoms experienced.
  • Findings: See "Diagnostic criteria for POTS."

One negative active stand test does not rule out a diagnosis of POTS; consider repeat testing based on clinical suspicion. [2]

Routine studies [1][2][7]

Additional studies [7][8]

Further evaluation in consultation with a specialist may be warranted based on clinical presentation and may include the following.

Icon of a lock

Register or log in , in order to read the full article.

Differential diagnosestoggle arrow icon

Comorbid conditions with POTS

Some differential diagnoses may also occur simultaneously with POTS, e.g.:

The differential diagnoses listed here are not exhaustive.

Icon of a lock

Register or log in , in order to read the full article.

Managementtoggle arrow icon

General principles [2][8]

  • POTS is typically not curable; therapy focuses on reducing symptoms and optimizing quality of life.
  • Educate all patients on nonpharmacological management (e.g., increased water and salt intake, exercise).
  • Pharmacological therapy (e.g., midodrine, fludrocortisone, and/or propranolol) is often required in addition to lifestyle modifications, especially for severe cases.
  • Manage comorbid conditions with POTS (e.g., ME/CFS, mast cell activation syndrome).
  • Refer to a specialist (e.g., cardiology, neurology) for severe or refractory features.

Specialist POTS care is limited; most patients are managed in primary care. [2][3]

Nonpharmacological management [2][4]

Educate patients on self-management strategies to improve circulating volume and venous return.

  • Increased water intake (3 liters per day) and salt intake (10 g per day) [2]
  • Avoidance of aggravating factors (e.g., heavy meals, alcohol intake, heat exposure)
  • Abdominal and leg compression garments
  • Personalized exercise therapy program (avoiding postexertional malaise) [2]
  • Physical counterpressure maneuvers as needed (e.g., leg crossing, squatting)
  • Sleeping with the head of the bed elevated 4–6 inches [2]

Pharmacological treatment [2][4]

  • No medication is FDA-approved to treat POTS.
  • The choice of agent is tailored to the clinical presentation and tolerability.
    • Consider medications that increase venous return for patients with:
    • Consider medications that reduce heart rate for patients with:
      • High HR when lying down and/or high 24-hour average HR
      • Palpitations as the predominant symptom
  • Titrate medications slowly and add additional medications one at a time if necessary. [8]
Pharmacotherapy for POTS [2][4]
‎Treatment mechanism Example agents Considerations
Increased venous return
  • Avoid lying supine within 3 hours of taking a dose. [2]
  • May worsen headache
Heart rate reduction
  • May worsen fatigue
  • Fewer side effects but more expensive
  • May worsen abdominal cramping and diarrhea
Icon of a lock

Register or log in , in order to read the full article.

Start your trial, and get 5 days of unlimited access to over 1,100 medical articles and 5,000 USMLE and NBME exam-style questions.
disclaimer Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer